Friday, December 09, 2016 1:51:27 PM
The human body is the most complicated structure that I know of and composed of a myriad of interconnected, yet different processes – many of which are controlled by feedback loops – just as the heating/air conditioning system in your home is controlled with a feedback loop regulated by the thermostat.
Briefly – the state of a neuron (or cell in general) is not an “all or nothing” endeavor – i.e. a neuron is not either dead or alive. A neuron, can be still partially functional (dysfunctional is a rather more appropriate term) when injured and dying – i.e. a “sick” neuron so to speak.
In the setting of neuronal insulations – a cascade of events take place often involving neuroinflammation (I have covered this, at length on YMB and Ihub to a lesser degree in the past) that often times end in neuronal death. Falconer66, whose posts have been most informative recently, has correctly described the process of mitochondrial-endoplasmic reticulum (ER) dissociation whereby the ER no longer can effenciently use the power supplied by the mitochondria to regulate internal neuronal/cellular processes often involving protein misfolding, etc.
When a large aggregate of neurons are chronically exposed to the neuroinflammatory cascade of events – there begins a futile cycle of neuronal death, inducing more neuroinflammation that in turn leads to further neuronal death – chronic neurodegeneration and depending on the regions of damage – may lead to Alzheimers dementia, other types of dementia, Parkinsons Disease (PD -if the basal ganglia/midbrain dopaminergic structures are involved), etc. The theory being that there is one complicated neuroinflammatory process that results in a multitude of different neurological pathologies.
What if there is an agent that can perhaps stop the herald steps of this complicated neuroiflammatory cascade that can lead to the different pathologies (that seem to result from a similar pathophysiological process)? What if this agent can allow a dysfunctional neuron, with disordered and dysfunctional mitochondria/ER regulation – to allow for the neuron to function more normally – restoring homeostasis? The theory, further advanced, suggests that if the chronic insulting process – chronic neuroinflammation – is halted, the body’s natural – “self healing” processes can supercede the degenerating processes caused by the futile cycle of chronic neurodegeneration.
In my opinion, this is why AVXL is so different from the other companies working in the Alzheimer’s space with the hackneyed “clearing of beta amyloid plaques” approach. It is more worthwhile, in my opinion, to target the processes that cause the plaques to develop in the first place. The plaques, being end products of misfolded proteins causing them to be insoluble, are not the cause of cognitive decline and why, I believe, this conventional approach taking by Lilly and Biogen is bound to fail.
Restoring natural cellular homeostasis is why I believe Anavex is at the forefront to the paradigm shift in treating neurodegenerative disorders. The company is small, it is promoting a theory that has never been promoted before by the top researchers in Alzheimers and in big pharma. The Semmelweis reflex is truly in effect with Anavex.
Semmelweis reflex: the tendency to reject new evidence or new knowledge because it contradicts established norms, beliefs or paradigms. The bias takes its name from the reaction of the medical community against the findings of Semmelweiss, the Hungarian physician who showed that hand-washing by physicians in an antiseptic solution before delivery reduced puerperal sepsis in the mother by 90%.
Good luck to all the long investors!
Recent AVXL News
- Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024 • GlobeNewswire Inc. • 10/31/2024 08:00:00 AM
- ZenaTech, Inc. (NASDAQ: ZENA) Software Company Acquisition • InvestorsHub NewsWire • 10/23/2024 12:03:31 PM
- Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia • GlobeNewswire Inc. • 10/17/2024 11:30:00 AM
- ZenaTech, Inc. (NASDAQ: ZENA) First US Trial of IQ Nano Drone for Inventory Management • InvestorsHub NewsWire • 10/15/2024 12:21:48 PM
- ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • InvestorsHub NewsWire • 10/01/2024 11:00:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 09:21:05 PM
- Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
- Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 09:21:49 PM
- Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference • GlobeNewswire Inc. • 07/28/2024 09:00:00 PM
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM
Rainmaker Worldwide Inc. Announces Strategic Partnership Between Miranda Water Technologies and Fleming College • RAKR • Nov 4, 2024 12:03 PM
North Bay Resources Announces Assays up to 9.5% Copper at Murex Copper Project, British Columbia • NBRI • Nov 4, 2024 9:00 AM
Rainmaker Worldwide Inc. to Assume Direct, Non-Dealer Sales of Miranda Water Technologies in U.S. and Mexico in First Quarter of 2025 • RAKR • Nov 4, 2024 8:31 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM